Cargando…

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited‐disease small cell lung cancer: protocol of ACIST study

BACKGROUND: Etoposide plus cisplatin (EP) combined with concurrent accelerated hyperfractionated thoracic radiotherapy (AHTRT) is the standard treatment strategy for unresectable limited‐disease (LD) small cell lung cancer (SCLC), which has remained unchanged for over two decades. Based on a previou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akagi, Kazumasa, Taniguchi, Hirokazu, Fukuda, Minoru, Yamazaki, Takuya, Ono, Sawana, Tomono, Hiromi, Suyama, Takayuki, Shimada, Midori, Gyotoku, Hiroshi, Takemoto, Shinnosuke, Yamaguchi, Hiroyuki, Dotsu, Yosuke, Senju, Hiroaki, Soda, Hiroshi, Mizowaki, Takashi, Monzen, Yoshio, Ikeda, Takaya, Nagashima, Seiji, Tasaki, Yutaro, Nakamura, Daisuke, Komiya, Kazutoshi, Nakatomi, Katsumi, Sasaki, Eisuke, Hirakawa, Koichi, Mukae, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376170/ https://www.ncbi.nlm.nih.gov/pubmed/35808894 http://dx.doi.org/10.1111/1759-7714.14555

Ejemplares similares

Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
por: Ikeda, Takaya, et al.
Publicado: (2020)

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
por: Dotsu, Yosuke, et al.
Publicado: (2021)

Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis
por: Takemoto, Shinnosuke, et al.
Publicado: (2021)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study
por: Tomono, Hiromi, et al.
Publicado: (2023)

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non‐squamous non‐small cell lung cancer
por: Takemoto, Shinnosuke, et al.
Publicado: (2017)

Proportion of biopsy specimens containing a tumor when compared to all biopsy specimens by transbronchial biopsy
por: Takemoto, Shinnosuke, et al.
Publicado: (2023)

Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma
por: Umeyama, Yasuhiro, et al.
Publicado: (2023)

Hypertrophic osteoarthropathy associated with lung cancer: Possible links among hypoxia‐inducible factor‐1α, vascular endothelial growth factor, and hypervascularization
por: Tagawa, Ryuta, et al.
Publicado: (2023)

Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases
por: Ogata, Ryosuke, et al.
Publicado: (2022)

Prediction of Anti-Cancer Drug-Induced Pneumonia in Lung Cancer Patients: Novel High-Resolution Computed Tomography Fibrosis Scoring
por: Gyotoku, Hiroshi, et al.
Publicado: (2020)

Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation
por: Dotsu, Yosuke, et al.
Publicado: (2020)

Pulmonary Artery Sarcoma Overexpressing Platelet-derived Growth Factor Receptor α
por: Takemoto, Shinnosuke, et al.
Publicado: (2017)

Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report
por: Taniguchi, Hirokazu, et al.
Publicado: (2021)

Intrathoracic amyloid tumors that presented as yellowish multinodular endobronchial protrusions with irregular vascularity and easy bleeding
por: Tomono, Hiromi, et al.
Publicado: (2019)

Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targets
por: Shimada, Midori, et al.
Publicado: (2023)

Vildagliptin‐induced ground‐glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic supplementation
por: Tanaka, Yasuhiro, et al.
Publicado: (2020)

Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer
por: Fukuda, Minoru, et al.
Publicado: (2017)

Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum
por: Sumiyoshi, Makoto, et al.
Publicado: (2017)

ACIST-FFR Study (Assessment of Catheter-Based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement)
por: Fearon, William F., et al.
Publicado: (2017)

Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy
por: Ogawara, Daiki, et al.
Publicado: (2017)

Pitfalls in diagnosis with the use of circulating tumor‐derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M
por: Ogawara, Daiki, et al.
Publicado: (2017)

Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma
por: Ikeda, Takaya, et al.
Publicado: (2018)

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
por: Ando, Takayuki, et al.
Publicado: (2015)

Continuous, hyperfractionated, accelerated radiotherapy (CHART).
por: Dische, S., et al.
Publicado: (1989)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Hyperfractionated abdominal reirradiation for gastrointestinal malignancies
por: Hunt, Andrew, et al.
Publicado: (2018)

Exploring the ethical complexities of do‐not‐attempt‐resuscitation orders using the approach of advance care planning
por: Ogata, Ryo, et al.
Publicado: (2023)

A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients
por: Imai, Hisao, et al.
Publicado: (2017)

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study
por: Soda, Hiroshi, et al.
Publicado: (2018)

Pulmonary pleomorphic carcinoma with few PD‐1‐positive immune cells and regulatory T cells that showed a complete response to nivolumab
por: Okamura, Kazuaki, et al.
Publicado: (2017)

Successful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G
por: Suyama, Takayuki, et al.
Publicado: (2018)

Hyperfractionated radiotherapy for re-irradiation of recurrent esophageal cancer
por: Takeda, Kazuya, et al.
Publicado: (2021)

Neoadjuvant short-course hyperfractionated accelerated radiotherapy (SC-HART) combined with S-1 for locally advanced rectal cancer
por: Doi, Hiroshi, et al.
Publicado: (2013)

Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy
por: Senju, Hiroaki, et al.
Publicado: (2018)

Tumor‐selective Distribution of an Active Metabolite of the 9‐Aminoanthracycline Amrubicin
por: Noguchi, Toshihiro, et al.
Publicado: (1998)

Corrigendum to ‘Neoadjuvant short-course hyperfractionated accelerated radiotherapy (SC-HART) combined with S-1 for locally advanced rectal cancer’(†)
por: Doi, Hiroshi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qgjbf56nl1chjhc82cn1s10r9o